Quotables
"The man with a new idea is a crank until the idea succeeds."
Samuel Clemens
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8153135 | Polysaccharide-polypeptide conjugate Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening... | 04/10/2012 |
| 8124095 | Fusion proteins for delivery of erythropoietin to the CNS The invention provides compositions, methods, and kits for increasing transport of a neurotrophin (e.g., erythropoietin (EPO)) across the blood brain barrier while allowing its activity to remain substantially intact. The neurotrophin (e.g., EPO) is transported acro... | 02/28/2012 |
| 8124094 | Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising... | 02/28/2012 |
| 8105600 | Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formul... | 01/31/2012 |
| 8088386 | Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders. ... | 01/03/2012 |
| 8084033 | Composition comprising a cell expressing an AC133 cell surface antigen and an antibody or antigen-binding fragment Compositions comprising a cell expressing an AC133 cell surface antigen and an antibody, or antigen binding fragment thereof, that specifically binds to the antigen are provided. Expression of the antigen is highly tissue specific. It is detected on a subset of hema... | 12/27/2011 |
| 8084034 | Proteins The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (par... | 12/27/2011 |
| 8071103 | Pharmaceutical composition comprising a human GLP-1 mimetibody The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or varian... | 12/06/2011 |
| 8067005 | Divalent antibody fragments Divalent antibody fragments are described, each of which has one or more interchain bridges containing a synthetic or naturally occurring polymer selected from a polyalkylene, polyakenylene, polyoxyalkylene or polysaccharide. Each bridge may be the residue of a homo... | 11/29/2011 |
| 8067006 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies ... | 11/29/2011 |
| 8012485 | Drug conjugate composition The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering ... | 09/06/2011 |
| 8007804 | Complement receptor 2 targeted complement modulators Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositio... | 08/30/2011 |
| 8007805 | Chimeric antigens for breaking host tolerance to foreign antigens Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking h... | 08/30/2011 |
| 8003613 | Methods and compositions for inducing apoptosis The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to ... | 08/23/2011 |
| 7994135 | Monomethylvaline compounds capable of conjugation to ligands Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro an... | 08/09/2011 |
| 7981423 | Rage fusion proteins Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an imm... | 07/19/2011 |
| 7981424 | RAGE fusion proteins, formulations, and methods of use thereof Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-... | 07/19/2011 |
| 7964195 | Ovr110 antibody compositions and methods of use The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr... | 06/21/2011 |
| 7964566 | Monomethylvaline compounds capable of conjugation to ligands Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro an... | 06/21/2011 |
| 7964567 | Monomethylvaline compounds capable of conjugation to ligands Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro an... | 06/21/2011 |
| 7951374 | Methods for inhibiting STAT3 signaling in immune cells Methods of enhancing antitumor activity of an immune cell comprising contacting the immune cell with a Stat3 inhibitor are described. Also described are methods of killing a tumor cell or inhibiting tumor growth in a subject comprising contacting an immune cell of t... | 05/31/2011 |
| 7947276 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently,... | 05/24/2011 |
| 7931903 | Internalizing anti-CD74 antibodies and methods of use The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful fo... | 04/26/2011 |
| 7906121 | Methods and compositions for generating bioactive assemblies of increased complexity and uses The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-an... | 03/15/2011 |
| 7901688 | Rage fusion proteins Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an imm... | 03/08/2011 |
| 7871622 | Stably tethered structures of defined compositions with multiple functions or binding specificities The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first mon... | 01/18/2011 |
| 7854932 | Immunogenic compositions comprising progastrin and uses thereof The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents th... | 12/21/2010 |
| 7833531 | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specifie... | 11/16/2010 |
| 7811571 | Polyallylamine conjugates and applications thereof for biological signal amplification Polyallylamine conjugates and applications thereof for biological signal amplification are provided by utilizing the essential amino group of polyallylamine to covalently bind with capture agents and signal molecules having the functional groups selected from a grou... | 10/12/2010 |
| 7811572 | Process for preparing purified drug conjugates The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purifica... | 10/12/2010 |
| 7794721 | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith A composition for treating a subject is provided. The composition includes a pentameric secretory IgM therapeutic. Formulating agents are mixed with the pentameric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufactur... | 09/14/2010 |
| 7758861 | Dye-sulfenates for dual phototherapy The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates bo... | 07/20/2010 |
| 7744891 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. ... | 06/29/2010 |
| 7736651 | Alpha emitting constructs and uses thereof The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, incl... | 06/15/2010 |
| 7736653 | Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably exte... | 06/15/2010 |
| 7736652 | Antibody fusion proteins: effective adjuvants of protein vaccination The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion protei... | 06/15/2010 |
| 7713528 | Method for in vivo delivery of active compounds using reagent conjugate This invention relates to novel reagent conjugates and a novel multi-step process for delivering active compounds to target analytes of interest in a patient for diagnostic and therapeutic purposes. According to the process, two novel reagents are bound to each othe... | 05/11/2010 |
| 7670605 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. ... | 03/02/2010 |
| 7670604 | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic agents. ... | 03/02/2010 |
| 7666424 | Methods of preparing and using single chain anti-tumor antibodies This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collect... | 02/23/2010 |
